Sabra Health Care (SBRA) Earnings Analysis
Sabra Health Care (SBRA) next reports earnings on 2026-08-03, consensus EPS 0.1711 USD. Last quarter (2026-04-29) it missed with EPS 0.16 USD vs 0.1667 USD est (-4%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 34.13.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SBRA next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | 0.1711 USD |
| Revenue estimate | 0.22B |
SBRA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-29 | 0.16 USD | 0.1667 USD | -4% | Miss |
| 2026-02-12 | 0.38 USD | 0.17 USD | +123.5% | Beat |
| 2025-08-04 | 0.38 USD | 0.37 USD | +2.7% | Beat |
| 2025-05-05 | 0.37 USD | 0.36 USD | +2.8% | Beat |
| 2025-02-19 | 0.36 USD | 0.36 USD | 0% | Beat |
| 2024-10-31 | 0.37 USD | 0.36 USD | +2.8% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
SBRA valuation and analyst view
| Trailing P/E | 34.13 |
|---|---|
| Trailing EPS | 0.61945 USD |
| Price / book | 1.99 |
| Dividend yield | 5.46% |
| Market cap | 5.53B |
| Analyst consensus | Hold (11 buy / 16 hold / 2 sell) |
| Avg price target | 22 USD |
Related research pages
Frequently asked questions
When is Sabra Health Care (SBRA)'s next earnings date?
Sabra Health Care is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 0.1711 USD and revenue estimate of 0.22B.
Did SBRA beat earnings last quarter?
In its 2026-04-29 report, SBRA posted EPS of 0.16 USD versus a 0.1667 USD estimate — a miss of 4%.
What is SBRA's earnings track record?
Over the last 6 reported quarters with consensus data, SBRA beat estimates 5 times (83%).
What is SBRA's current P/E ratio and EPS?
SBRA trades at a trailing P/E of 34.13 on trailing EPS of 0.6194496448199837 USD.
What do analysts rate SBRA?
Analyst consensus is "Hold" across 29 ratings (0 strong buy, 11 buy, 16 hold, 2 sell, 0 strong sell). Average 12-month price target: 22 USD.